Olav Dalgard

Summary

Affiliation: The Norwegian Radium Hospital
Country: Norway

Publications

  1. ncbi [Hepatitis C--a health problem also in Norway]
    Inger Sofie Samdal Vik
    Avdeling for virologi Nasjonalt folkehelseinstitutt Geitmyrsveien 75 0462 Oslo
    Tidsskr Nor Laegeforen 128:563-6. 2008
  2. ncbi Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
    Olav Dalgard
    Department of Medicine, Aker University Hospital, Oslo, Norway
    Hepatology 40:1260-5. 2004
  3. ncbi Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection
    Olav Dalgard
    Department of Microbiology Ullevål University Hospital, Oslo, Norway
    Drugs 66:1807-15. 2006
  4. ncbi Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
    Olav Dalgard
    Infectious Disease Department, Ulleval University Hospital, Oslo, Norway
    Hepatology 47:35-42. 2008
  5. ncbi IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
    Amir Moghaddam
    Furst Medisinsk Laboratorium, Oslo, Norway
    Hepatology 53:746-54. 2011
  6. ncbi Follow-up studies of treatment for hepatitis C virus infection among injection drug users
    Olav Dalgard
    Unit of Hepatology, Aker University Hospital, Oslo, Norway
    Clin Infect Dis 40:S336-8. 2005
  7. ncbi Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection
    Olav Dalgard
    Medical Department Aker University Hospital, Oslo, Norway
    Hepatology 39:74-80. 2004
  8. ncbi Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
    Håvard Midgard
    Department of Gastroenterology, Aker University Hospital, Oslo, Norway
    Scand J Gastroenterol 45:1503-8. 2010
  9. ncbi Short treatment to patients with genotype 2 or 3
    Olav Dalgard
    Hepatology 48:694. 2008
  10. ncbi [Treatment of chronic hepatitis C]
    Helge Bell
    Seksjon for leversykdommer Medisinsk klinikk Aker universitetssykehus 0514 Oslo
    Tidsskr Nor Laegeforen 122:926-8. 2002

Collaborators

Detail Information

Publications10

  1. ncbi [Hepatitis C--a health problem also in Norway]
    Inger Sofie Samdal Vik
    Avdeling for virologi Nasjonalt folkehelseinstitutt Geitmyrsveien 75 0462 Oslo
    Tidsskr Nor Laegeforen 128:563-6. 2008
    ..The aim of this article is to describe the clinical course, microbiological diagnostic approaches, therapy, prophylaxis and public health aspects of Hepatitis C infection...
  2. ncbi Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
    Olav Dalgard
    Department of Medicine, Aker University Hospital, Oslo, Norway
    Hepatology 40:1260-5. 2004
    ..The results need to be confirmed in a randomized, controlled study before this treatment approach can be recommended, particularly for patients with genotype 3 and high viral load or severe fibrosis...
  3. ncbi Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection
    Olav Dalgard
    Department of Microbiology Ullevål University Hospital, Oslo, Norway
    Drugs 66:1807-15. 2006
    ..For patients with genotype 3, a univocal recommendation on treatment duration cannot be made. However, ongoing trials will probably clarify this aspect...
  4. ncbi Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
    Olav Dalgard
    Infectious Disease Department, Ulleval University Hospital, Oslo, Norway
    Hepatology 47:35-42. 2008
    ....
  5. ncbi IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
    Amir Moghaddam
    Furst Medisinsk Laboratorium, Oslo, Norway
    Hepatology 53:746-54. 2011
    ..4 × 10(-5) ; rs8099917, P = 7.3 × 10(-6) ). CONCLUSION: Polymorphisms near the IL28B gene show association with rapid viral response but not sustained viral response to PEG-IFN/ribavirin therapy in HCV genotype 3-infected patients...
  6. ncbi Follow-up studies of treatment for hepatitis C virus infection among injection drug users
    Olav Dalgard
    Unit of Hepatology, Aker University Hospital, Oslo, Norway
    Clin Infect Dis 40:S336-8. 2005
    ..It has not been determined whether any of these cases were actual reinfections. Available data suggest that the rate of long-term response to treatment for HCV infection is excellent in IDUs...
  7. ncbi Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection
    Olav Dalgard
    Medical Department Aker University Hospital, Oslo, Norway
    Hepatology 39:74-80. 2004
    ..In conclusion, chronic HCV infection per se did not negatively affect the HRQOL of active injecting drug users. Those who thought they were infected had a lower HRQOL scores than those who believed they were not infected...
  8. ncbi Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
    Håvard Midgard
    Department of Gastroenterology, Aker University Hospital, Oslo, Norway
    Scand J Gastroenterol 45:1503-8. 2010
    ..The aim of this study was to examine the significance of native country for the stage of liver fibrosis in a population of HCV patients of Pakistani or Scandinavian origin living in Oslo...
  9. ncbi Short treatment to patients with genotype 2 or 3
    Olav Dalgard
    Hepatology 48:694. 2008
  10. ncbi [Treatment of chronic hepatitis C]
    Helge Bell
    Seksjon for leversykdommer Medisinsk klinikk Aker universitetssykehus 0514 Oslo
    Tidsskr Nor Laegeforen 122:926-8. 2002